Late presentation of HIV infection: A consensus definition

HIV Medicine

Volumn 12, Issue 1, 2011, Pages 61-64

  Antinori, A ^a   Coenen, T ^b   Costagiola, D ^c   Dedes, N ^d   Ellefson, M ^e   Gatell, J ^f   Girardi, E ^a   Johnson, M ^l   Kirk, O ^e   Lundgren, J ^e   Mocroft, A ^g   D'Arminio Monforte, A ^h   Phillips, A ^g   Raben, D ^e   Rockstroh, J K ⁱ   Sabin, C ^g   Sonnerborg A ^j   De Wolf, F ^k  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b National Institute for STI and AIDS Control in the Netherlands   (Netherlands)

^c INSERM   (France)

^d EUROPEAN AIDS TREATMENT GROUP   (Belgium)

^e Rigshospitalet   (Denmark)

^f UNIVERSITY OF BARCELONA   (Spain)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h SAN PAOLO HOSPITAL   (Italy)

ⁱ UNIVERSITY HOSPITAL BONN   (Germany)

^j KAROLINSKA INSTITUTE   (Sweden)

^k STICHTING HIV MONITORING   (Netherlands)

^l ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Definition; Diagnosis; Europe; HIV; Late presentation

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; EUROPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

CD4 LYMPHOCYTE COUNT; CONSENSUS; DELAYED DIAGNOSIS; EUROPE; HEALTH POLICY; HIV INFECTIONS; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; TIME FACTORS;

EID: 78650085770     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00857.x     Document Type: Article

References (28)

1. Fisher M. Late diagnosis of HIV infection: major consequences and missed opportunities. Curr Opin Infect Dis 2008; 21: 1-3.
2. Adler A, Mounier-Jack S, Coker RJ. Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care 2009; 21: 284-293.
3. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
4. Chadborn TR, Baster K, Delpech VC et al. No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS 2005; 19: 513-520.
5. Lanoy E, Mary-Krause M, Tattevin P et al. for the clinical epidemiology group of the French hospital database on HIV infection. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 2007; 12: 89-96.
6. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4<200 cells/microL) with HIV infection. HIV Med 2004; 5: 93-98.
7. Marks G, Crepaz N, Janssen RS et al. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 26: 1447-1450.
8. Phillips AN, Staszewski S, Weber R et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286: 2560-2567.
9. Phillips AN, Lepri AC, Lampe F, Johnson M, Sabin CA. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 2003; 17: 1863-1869.
10. Sterne JA, May M, Costagliola D et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-1363.
11. European AIDS Clinical Society (EACS). HIV Treatment Guidelines 2009. Available at (accessed January 2010).
12. World Health Organisation (WHO). WHO Adult ART Treatment Guidelines 2006. Available at (accessed January 2010).
13. British HIV Association (BHIVA). HIV Treatment Guidelines. Available at (accessed January 2010).
14. Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS society-USA panel. JAMA 2008; 300: 555-570.
15. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9: 65-71.
16. Guiguet M, Boué F, Cadranel J et al. for the Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10: 1152-1159.
17. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22: 2409-2418.
18. Mocroft A, Reiss P, Gasiorowski J et al. for the EuroSIDA Study Group. Serious fatal and non-fatal non-AIDS-defining illnesses (non-ADI) in Europe. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [Abstract 707].
19. Gazzard B, Lundgren J, eds. The HIV in Europe 2007 initiative: issues, challenges and opportunities for addressing optimal testing and earlier care. HIV Med 2008; 9 (Suppl. 2): 1-40.
20. Antinori A, Johnson M, Moreno S, Yazdanpanah Y, Rockstroh JK. Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation. Antivir Ther 2010; 15: 31-35.
21. Available at (accessed December 2009).
22. Available at (accessed January 2010).
23. The UK Collaborative HIV Cohort (CHIC). Steering Committee. Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS 2010; 24: 723-727.
24. European AIDS Clinical Society (EACS). HIV Treatment Guidelines 2005. Previously available at (accessed July 2007).
25. Podlekareva D, Mocroft A, Dragsted UB et al. for the EuroSIDA study group. Factors associated with development of opportunistic infections in HIV-1 infected adults with high CD4 cell counts: a EuroSIDA study. J Infect Dis 2006; 194: 633-641.
26. Phillips AN, Gazzard B, Gilson R et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naïve individuals with high CD4 cell count. AIDS 2007; 21: 1717-1721.
27. Moore RD, Gebo KA, Lucas GM, Keruly JC. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis 2008; 47: 1102-1104.
28. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009, pp. 1-161. Available at (accessed January 2010).